Journal
PATHOLOGY INTERNATIONAL
Volume 62, Issue 12, Pages 792-801Publisher
WILEY
DOI: 10.1111/pin.12019
Keywords
cancer stem cell markers; lung adenocarcinoma; prognosis
Categories
Funding
- Ministry of Education, Culture, Sports, and Science of Japan (Tokyo Japan)
- Smoking Research Foundation (Tokyo, Japan)
- Yokohama Medical Facility (Yokohama, Japan)
- Grants-in-Aid for Scientific Research [23790411, 24592511, 23590428, 24590421] Funding Source: KAKEN
Ask authors/readers for more resources
The present study investigated expression profiles of the potential CSC markers including CD133, CD44, ALDH1, and beta-catenin, and evaluated their prognostic value in lung adenocarcinomas. One-hundred-and-seventy-seven tumors (stage I) were immunohistochemically examined for the expression of these markers, and thresholds to subdivide expression levels were determined using receiver operating characteristics curves. Tumors with high levels of CD133 (adjusted hazard ratio (HR) 4.55 (95% confidence interval (CI) 1.2616.40, P?=?0.021), CD44 (HR 3.73, 95% CI 1.2011.58, P?=?0.023) or ALDH1 (HR 3.61, 95% CI 1.0912.3, P?=?0.036), but not beta-catenin (HR 2.43, 95% CI 0.5910.8, P?=?0.220), showed a significantly higher risk of recurrence than the corresponding low expressers. In conclusion, levels of CD133, CD44, and ALDH1 had independent prognostic value to predict the recurrence of lung adenocarcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available